◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Ping An Insurance (Group) Company of China, Ltd. (2318) Revenue 2022–2025

Name: Ping An Insurance (Group) Company of China, Ltd. (2318) revenue history 2022-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Ping An Insurance (Group) Company of China, Ltd. annual revenue for fiscal 2025 was CNY 927.9 billion, an increase of 1.2% from CNY 916.6 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

2318 Annual Revenue

Revenue (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 927.9B	CNY 916.6B	CNY 802.1B	CNY 763.9B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2318 Quarterly Revenue

Revenue (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	CNY 186.4B	CNY 187.5B	CNY 302.5B	CNY 235.8B	CNY 202.1B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

8750 Revenue — Daiichi Life Group, Inc.
8795 Revenue — T&D Holdings, Inc.
7181 Revenue — Japan Post Insurance Co., Ltd.
8729 Revenue — SONY FINANCIAL GROUP INC
2628 Revenue — China Life Insurance Company Limited
1299 Revenue — AIA Group Limited

More 2318 metrics: Net Income · EPS · Free Cash Flow

All 2318 financial statements → Interactive 2318 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.